The deal includes a Phase III clinical trial involving 30,000 participants and a pediatric trial.
In addition, the company collaborates with international organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI), the Gavi the Vaccine Alliance and the World Health Organization (WHO) for the fair allocation and distribution of the vaccine worldwide.
The UK-based drug maker said it is also in discussions with governments around the world to increase access.
AstraZeneca, which recently joined forces with the UK government to support Oxford University’s vaccine, said it will deliver the UK from September.
“This pandemic is a global tragedy and is a challenge for all of humanity. We have to defeat the virus together or it will continue to inflict enormous personal suffering and leave long lasting economic and social scars in all countries around the world. , ”Pascal Soriot, CEO of AstraZeneca, said in a statement.
“We are so proud to be partnering with Oxford University to turn their groundbreaking work into a drug that can be produced worldwide. We would like to thank the US and UK governments for their significant support in accelerating the development and production of the vaccine. We will do anything to make this vaccine fast and widely available, ”Soriot said.
AstraZeneca has now concluded its licensing agreement with Oxford University for recombinant adenovirusvaccine.
The license for the vaccine, formerly ChAdOx1 nCoV-19 and now known as AZD1222, follows the recent global development and distribution agreement with the university’s Jenner Institute and Oxford Vaccine Group.
AstraZeneca has also agreed to support the establishment of a joint research center at Oxford University for research into pandemic preparedness.
A phase I / II clinical trial of AZD1222 began last month to assess the safety, immunogenicity and efficacy of over 1,000 healthy volunteers aged 18 to 55 across several trial centers in southern England.
Data from the trial is expected soon, which, if positive, will lead to delays in a number of countries.
AstraZeneca said it recognizes that the vaccine may not work, but is committed to continuing the clinical program at speed and upscale manufacturing at risk.